Center for Life Sciences Innovation
ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play. The Center’s mission is to study and advance the many technology, economic, and policy factors underpinning successful life sciences innovation—from how new technologies like artificial intelligence, genomics, and gene editing are powering the next generation of biomedical innovation to the economics of life sciences innovation, including the role of IP and incentives therein; international competitiveness in life sciences innovation; and foremost the optimal set of public policies, at home and abroad, to spur greater levels of much-needed biopharmaceutical innovation.
How Japan Squandered Its Biopharmaceutical Competitiveness: A Cautionary Tale
Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”
Going, Going, Gone? To Stay Competitive in Biopharmaceuticals, America Must Learn From Its Semiconductor Mistakes
Five Fatal Flaws in Rep. Katie Porter’s Indictment of the U.S. Drug Industry
The Impact of China’s Policies on Global Biopharmaceutical Industry Innovation
March 29, 2022
How Using March-in Rights Would Threaten America’s Research Universities
ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.
April 29, 2021
How Intellectual Property Has Played a Pivotal Role in the Global COVID-19 Response
ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.
April 21, 2021
Seizing the Transformative Opportunity of Multi-cancer Early Detection
ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.
March 25, 2021
March-In Rights for Federally Funded Inventions: A Primer
ITIF and the Bayh-Dole Coalition hosted a joint video webinar that will clarify the provision’s intent and explain once and for all how Bayh-Dole’s march-in right can and cannot be used.
December 16, 2020
Lessons Learned From Global Life Sciences Ecosystems in the COVID-19 Pandemic
ITIF hosted a discussion on this critical issue. The event featured a keynote address by Simon Tripp of TEConomy Partners, author of the new report “Response and Resilience: Lessons Learned from Global Life Sciences Ecosystems in the COVID-19 Pandemic,” followed by an expert panel of respondents.
Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation
Associate Vice President for Federal Affairs, University of Pennsylvania
Managing Director, Bay City Capital
Partner, Irell & Manella, LLP
Cain Brothers & Company Professor of Healthcare, Columbia University Graduate School of Business
Assistant Professor of Medicine, Harvard Medical School
Founding President and CEO, National Minority Quality Forum
More From the Center
August 5, 2022|Blogs
Senate Reconciliation Legislation Fails to Reconcile the Interests of Biomedical Innovation and Drug Price Affordability
The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.
July 8, 2022|Blogs
Senate Democrats’ Drug Price Proposal Would Slow the Pace of New Drug Discovery
Congress should ignore pressure from progressive activists who want to use drug price controls to move to a government-led drug discovery and production system and instead focus on more pragmatic reforms.
June 24, 2022|Blogs
Postmortem on a Pyrrhic Victory for IP Foes at the WTO
The WTO’s approval of a TRIPS waiver for IP related to COVID-19 vaccines is essentially a shotgun blast completely missing the broadside of a barn.
June 17, 2022|Blogs
No, America’s Drug Prices Aren’t Climbing Radically Out of Control
The United States uniquely leads the world in innovating new drugs and getting them to patients first while sustaining a globally competitive industry and over time making drugs affordable by incentivizing competition and creating generic pathways.
June 6, 2022|Publications
About ITIF’s Center for Life Sciences Innovation
ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play in advancing the technology, economic, and policy factors that underpin it.
March 15, 2022|Op-Eds & Commentary
‘March-In’ Advocates Continue the Assault on Life-Sciences Innovation System
America’s world-leading life-sciences innovation system is a product of myriad policies, but one that is all too often overlooked is the Bayh-Dole Act, which gives IP rights to universities that produce innovation with federally funded R&D.
November 22, 2021|Op-Eds & Commentary
Drug Price Controls Are Bad Policy. Congress Should Instead Double Down on Innovation to Boost Productivity in Biopharma R&D
Capitol Hill is awash in proposals to stem allegedly out-of-control drug prices, but in their zealousness to rein in drug prices, policymakers risk imperiling drug innovation to the detriment of patients and the economy. The better way to produce more medical cures at lower cost over the long haul will be to double down on innovation, not deter it.